Virus pandemics have happened, are happening and will happen again. In recent decades,
the rate of zoonotic viral spillover into humans has accelerated, mirroring the expansion of …

A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-
based treatment regimens, often because of drug resistance-associated substitutions (RAS) …

Direct‐acting antivirals have become available for treating chronic HCV (hepatitis C virus)
infection in adults and, recently, in children at least 12 years old. Our aim was to investigate …

Background Despite the high sustained virological response rates achieved with current
directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5–10% of …

Background Although most currently used regimens for Hepatitis C virus (HCV) infections
can be initiated without prior knowledge of genotype and subtype, genotyping is still useful …

Based on high efficacy and safety demonstrated in clinical trials, treatment with glecaprevir/
pibrentasvir (G/P) for 8 weeks is recommended for hepatitis C virus (HCV)–infected patients …

Hepatitis C virus (HCV) genotype and subtype (1a/1b) identification is needed to tailor anti-
HCV therapy. Currently available methods accurately identify the genotype and differentiate …

Biological microarrays (biochips) are analytical tools that can be used to implement complex
integrative genomic and proteomic approaches to the solution of problems of personalized …

Accurate subtyping of hepatitis C virus genotype 1 (HCV-1) remains clinically and
epidemiologically relevant. The Abbott HCV Genotype Plus RUO (GT Plus) assay, targeting …

Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and
86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV …